Background
==========

Over the past 40 years, a marked decline in daily smoking prevalence in Poland has been observed \[[@b1-medscimonit-25-6322],[@b2-medscimonit-25-6322]\]. It is estimated that between 1976 and 2014, smoking prevalence has declined from 73% to 28% among males and from 30% to 19% among females \[[@b1-medscimonit-25-6322]\]. According to the data from the Chief Sanitary Inspectorate, in 2017, one-quarter of Poles aged ≥15 years old smoked cigarettes regularly \[[@b3-medscimonit-25-6322]\]. While the prevalence of tobacco use among Poles is monitored \[[@b1-medscimonit-25-6322]--[@b3-medscimonit-25-6322]\], electronic nicotine delivery systems, including electronic cigarettes (e-cigarettes) are gaining popularity \[[@b4-medscimonit-25-6322]--[@b6-medscimonit-25-6322]\].

Electronic cigarettes are battery-operated devices with a heating mechanism that heats the dedicated inhalation solution, producing an aerosol (called vapor) which is inhaled into the lungs \[[@b7-medscimonit-25-6322]\]. There are multiple models of e-cigarette devices and a variety of flavor variants of the inhalation solution (called e-liquids) \[[@b8-medscimonit-25-6322]\]. Chemical analysis of e-cigarette vapor and cigarette smoke revealed that e-cigarette use emits fewer numbers and lower levels of toxicants compared to cigarette smoking \[[@b9-medscimonit-25-6322]--[@b11-medscimonit-25-6322]\]. However, there is growing evidence from human-based studies showing potential harmful effects of e-cigarette use \[[@b12-medscimonit-25-6322]--[@b15-medscimonit-25-6322]\]. Due to the ambiguity of evidence on the impact of e-cigarettes on health, and the lack of long-term prospective cohort studies on e-cigarettes, there is a wide debate whether e-cigarettes can be used as a harm reduction tool \[[@b9-medscimonit-25-6322],[@b16-medscimonit-25-6322]--[@b18-medscimonit-25-6322]\]. According to the US National Academies of Sciences, Engineering, and Medicine (NASEM) report, e-cigarettes may pose a lower risk for health compared to cigarette smoking, but also can encourage young individuals who start with e-cigarettes to switch to combustible cigarettes ("gateway effect") \[[@b9-medscimonit-25-6322]\]. The NASEM committee of experts concluded that more research is needed to assess the potential impact of e-cigarette use on public health at the individual and the population levels \[[@b9-medscimonit-25-6322]\].

Controversy around whether e-cigarettes will reduce or induce harm has resulted in e-cigarette regulation that varies between countries, ranging from lack of regulation to completely ban on e-cigarette sale or use \[[@b19-medscimonit-25-6322]\]. In Poland, e-cigarettes are classified as tobacco related products and regulated by the amendment of the National Tobacco Control Act (Journal of Laws, Item 1331, 2016), which has been in force since September 2016 \[[@b20-medscimonit-25-6322]\]. Regulation sets rules on sale and advertising as well as packaging and labelling of e-cigarettes \[[@b20-medscimonit-25-6322]\]. Sale or distribution of e-cigarettes to minors under 18 years, cross-border distance sales, and sale via vending machines or self-service systems are prohibited. There is also a ban on e-cigarette use in public places, including hospitals and public transportation \[[@b20-medscimonit-25-6322]\]. The amendment also introduced a ban on advertising, promotion, and sponsorship related to e-cigarettes. The same rules apply to e-cigarettes with and without nicotine \[[@b20-medscimonit-25-6322]\].

Healthcare professionals have a prominent role to play in addressing the tobacco epidemic \[[@b21-medscimonit-25-6322]--[@b23-medscimonit-25-6322]\]. Evidence shows that brief interventions to smokers by healthcare professionals can increase rates of smoking cessation \[[@b22-medscimonit-25-6322],[@b23-medscimonit-25-6322]\]. To facilitate the treatment of a smoking patient, in many countries national guidelines for smoking cessation were developed \[[@b2-medscimonit-25-6322],[@b24-medscimonit-25-6322]--[@b26-medscimonit-25-6322]\]. The Polish smoking cessation guidelines recommend healthcare professionals (especially primary care physicians) systematically identify smokers and provide a minimum intervention on smoking cessation based on the "Five As" (ask, advise, assess, assist, arrange) \[[@b26-medscimonit-25-6322]\]. The growing interest of patients in e-cigarettes has led some countries to update their smoking cessation guidelines to information regarding e-cigarettes \[[@b27-medscimonit-25-6322],[@b28-medscimonit-25-6322]\]. In the United Kingdom, the National Institute for Health and Care Excellence published guidelines for healthcare professionals on how to discuss abut e-cigarettes with the patients \[[@b27-medscimonit-25-6322]\].

According to data from a cross-sectional survey of 27 901 EU citizens in 2017, 15% of Europeans aged 15 years or older declared at least one-time use of e-cigarettes and 2% were regular e-cigarette users \[[@b29-medscimonit-25-6322]\]. In Poland, the prevalence of e-cigarette use among adults decreased from 3% in 2013 to 2% in 2017 \[[@b3-medscimonit-25-6322]\]. The highest prevalence was observed among adolescents \[[@b6-medscimonit-25-6322],[@b30-medscimonit-25-6322]\]. Between 2010 and 2016, in a group of students aged 15--19 years old, the proportion of regular exclusive e-cigarette users increased from 2% in 2010--2011 to 11% in 2015--2016 \[[@b31-medscimonit-25-6322]\]. Among e-cigarettes users, the dominant group are dual users who regularly use other nicotine containing products as well as e-cigarettes \[[@b5-medscimonit-25-6322],[@b30-medscimonit-25-6322],[@b31-medscimonit-25-6322]\]. It is estimated that every fourth teenager in Poland is a dual user \[[@b30-medscimonit-25-6322]\].

The growing popularity of e-cigarettes makes more and more people ask their doctor for advice on e-cigarettes \[[@b28-medscimonit-25-6322]\]. Currently there is a lack of national guidelines regarding e-cigarettes in Poland. Due to the lack of recommendations developed by national scientific committees, guidance to patients depends on the individual decision of physicians and is shaped by physicians' perceptions of e-cigarettes. As healthcare professionals hold diverse views about the efficacy and safety of electronic nicotine delivery systems \[[@b32-medscimonit-25-6322]\], it is important to know how e-cigarettes are perceived by physicians. Therefore, the objectives of this study were to assess the knowledge and beliefs about e-cigarettes among physicians in Poland.

Material and Methods
====================

Participants
------------

A questionnaire-based survey was conducted between September and December 2018. Within Poland, each physician must attend a public health training course within 5--6 years of beginning their profession. The participation in the course is compulsory for each of 25 000 physician undergoing specialty in Poland. The participants in the courses are selected randomly and represented different regions and healthcare institutions from all over Poland. We approached physicians attending the training courses held during September, October, and November 2018 (8 different courses). All 500 physicians attending these specialist training courses delivered at the School of Public Health, Centre of Postgraduate Medical Education (Warsaw, Poland) during this period were eligible to take the survey.

Study questionnaire
-------------------

The research tool was a self-administered questionnaire developed for the purpose of this study. The questionnaire was developed in Polish. In preparation of the questionnaire, we analyzed the previously published studies on the perceptions of e-cigarettes among healthcare professionals \[[@b28-medscimonit-25-6322],[@b33-medscimonit-25-6322],[@b34-medscimonit-25-6322]\].

The questionnaire included 24 questions concerning beliefs and attitudes about e-cigarettes. Additional questions also addressed background information including age, sex, level of training, specialty, years of professional experience, practice type, and practice location.

E-cigarette awareness was assessed by the question "Are you aware of electronic cigarettes (commonly called e-cigarettes)?" ("Yes"/"No"). An additional question regarding the source of knowledge about e-cigarettes was addressed to all participants who declared being aware of e-cigarettes. To measure physicians' perceptions of e-cigarettes, a survey containing 22 questions regarding e-cigarettes was distributed to the attendees of the specialist training courses ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}). Questions regarding individual beliefs and attitudes about e-cigarettes were divided into 3 blocks: 1) health effects of e-cigarettes use, 2) addictive potential of e-cigarettes use, and 3) regulations concerning e-cigarettes. All 22 questions ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}) were meant to assess attitudes and beliefs with 4-point response scale: 1="totally disagree", 2="rather disagree", 3="rather agree" and 4="totally agree".

Repeatability of the prepared questionnaire was assessed by conducting it twice in an interval of 5 days among 14 physicians. Questionnaires as well as the form of distribution in both samples were identical. Kappa coefficients for the critical questions ranged from 0.88 to 0.96 so as these values were greater than 0.80 all questions were included in the final questionnaire.

A paper-based questionnaire was delivered to each of the 500 participants by a member of the research team. Participation in the study was voluntary and anonymous. Informed verbal consent was obtained from all individual participants involved in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statistical analysis
--------------------

For assessment of repeatability, Fleiss' kappa coefficients were calculated using SAS (SAS Institute Inc., Cary, NC, USA). The data was analyzed with Statistica 12 Software (TIBCO Software Inc., Palo Alto, CA, USA). Normality of distributions of continuous variables was assessed by the Shapiro-Wilk test. The distribution of categorical variables was shown by frequencies and proportions along with 95% confidence intervals. The chi-square test was used to compare categorical variables. Statistical inference was based on the criterion *P*\<0.05.

Depending on the level of professional development, participants were allocated to either a specialist-in-training group (specialty ongoing) or a specialist group (specialty completed). Based on self-declared field of medical practice, participants were assigned to a surgical or a non-surgical specialty.

Results
=======

Data were obtained from 412 physicians (64.3% females), with a response rate of 82.4%. The average age of the respondents was 31.9±5.7 years, with no age differences between males and females (*P*\>0.05). The vast majority of participants were physicians-in-training (85.7%). Physicians from 52 different specialties (out of 77 available specializations) took part in the survey. A total of 72.8% of all participants were trained in non-surgical specialties, mostly in internal medicine (116 participants) or pediatrics (86 participants). The predominant group of participants (89.1%) declared hospital as a place of primary employment. Over half of the physicians practiced in cities with more than 500 000 residents. Detailed participant characteristics are presented in [Table 2](#t2-medscimonit-25-6322){ref-type="table"}.

Knowledge about e-cigarettes
----------------------------

Among participants who were aware of e-cigarettes, the main sources of information about e-cigarettes were news stories (67.2%) or points of sale of e-cigarettes (67.6%). Over half of respondents (55.7%) indicated having learnt about e-cigarettes from family members or friends and only 20.9% of physicians gained knowledge about e-cigarettes from scientific articles or professional medical press ([Figure 1](#f1-medscimonit-25-6322){ref-type="fig"}).

Approximately 50.2% of respondents declared moderate knowledge about e-cigarettes and 24.3% of respondents rated their knowledge as poor ([Table 3](#t3-medscimonit-25-6322){ref-type="table"}). Willingness to learn more about e-cigarettes was declared by the majority of participants (78.1%) as presented in [Table 3](#t3-medscimonit-25-6322){ref-type="table"}. Females declared their willingness to learn more often than males (82.6% versus 70.1%; *P*=0.003). There were no significant differences in the perception of self-reported knowledge (*P*\>0.05) about e-cigarettes between physicians trained in the surgical or non-surgical specialties. Nevertheless, physicians trained in non-surgical specialties declared willingness to learn more about e-cigarettes more often (83.2%), compared to those trained in surgical specialties (67.9%; *P*=0.003). Specialists more often declared a good or very good level of knowledge about e-cigarettes (33.9%) compared to physicians-in-training (21.3%; *P*=0.01).

Health effects of e-cigarettes
------------------------------

The vast majority of participants (96.5%) agreed ("rather agree" or "totally agree") with the statement that e-cigarette use is harmful to the user's health and 80.5% agreed that exhaled e-cigarette aerosol is harmful to bystanders ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}). Among participants, 40.9% disagreed ("rather disagree" or "totally disagree") that e-cigarettes are less harmful than conventional cigarettes. Overall, according to the respondents, e-cigarettes are carcinogenic (86.1%), increase the risk of cardiovascular diseases (89.7%), and increase the risk of chronic lung diseases (85.2%). However, over one-third of physicians (36.4%) agreed with the statement that the risk of cancer is lower for the use of e-cigarettes compared to smoking conventional cigarettes and almost half of participants agreed that e-cigarette use, compared to cigarette smoking, is associated with a lower risk of cardiovascular or chronic lung diseases ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}).

Males more often agreed with the statement that, in contrast to conventional smoking, e-cigarette use is associated with lower risk of cancer (59.3% versus 71.5%; *P*=0.01), cardiovascular diseases (51.2% versus 66.7%; *P*=0.03), and chronic lung diseases (51.1% versus 67.3%; *P*=0.01). Specialists compared to physicians-in-training more often disagreed with the statement that e-cigarettes are less harmful than conventional cigarettes (66.6% versus 36.7%; *P*=0.0001). Participants who declared a hospital as a place of primary employment, compared to those who practice in ambulatory care, more often agreed with the statement that e-cigarettes are carcinogenic (86.6% versus 82.1%;*P*=0.02) and increase the risk of chronic lung diseases (86.7% versus 73.4%; *P*=0.02).

Addictive potential of e-cigarettes
-----------------------------------

Almost all of the respondents (97.1%) agreed with the statement that you can become addicted to e-cigarettes, and the majority (79.8%) disagreed that e-cigarettes are less addictive than conventional smoking ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}). The statement that e-cigarettes could be a "gateway" to conventional smoking was supported by 87% of participants. Among participants, 13.4% agreed that e-cigarettes should be recommended as a smoking cessation method, and 34% agreed that smokers who do not want to quit smoking should be encouraged to switch to e-cigarettes ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}).

Respondents who practice mainly in a hospital responded more often than their colleagues in the ambulatory care that they disagreed with the statement that e-cigarettes should be recommended as a smoking cessation tool (88.7% versus 68.9%; *P*=0.001). Among physicians, there were no statistically significant differences in the perceptions of health effects and addictive potential of e-cigarettes depending on the physicians' specialty or practice location (*P*\>0.05).

Legal regulations for e-cigarettes
----------------------------------

As high as 84.3% of the participants agreed that the promotion and advertising of e-cigarettes should be banned. Most respondents also agreed that e-cigarette use should be prohibited for minors (97.1%), in public places (88.8%), and indoors (91.7%) ([Table 1](#t1-medscimonit-25-6322){ref-type="table"}). There were no differences (*P*\>0.05) in perceptions of legal provisions regarding e-cigarettes depending on the sex, level of training, specialty, practice type and practice location.

Discussion
==========

To the authors' best knowledge this is one of the biggest studies aiming to assess knowledge and beliefs concerning e-cigarette use among physicians representing various medical specialties, and the only one conducted among physicians in Poland. In our study almost all respondents (99.8%) were aware of e-cigarettes, which is a higher prevalence of awareness compared to those reported in the general population in Europe and US \[[@b35-medscimonit-25-6322],[@b36-medscimonit-25-6322]\]. Such a high awareness of e-cigarettes may be due to the fact that this issue was widely discussed in the mass media, especially because the first e-cigarette regulation was introduced in 2016 by the amendment of the National Tobacco Control Act \[[@b20-medscimonit-25-6322]\]. According to this document, e-cigarettes are considered equivalent to conventional tobacco cigarettes and this statement caused a great deal of discussion in the media.

We have observed that only 21% of physicians get information about e-cigarettes from scientific articles. Most participants learned about e-cigarettes from non-scientific sources such as news stories or storefronts. Information obtained from such sources are not scientifically verified and might be biased. This poses a threat that education and guidance about e-cigarettes delivered by physicians is not based on evidence. Similar results were observed among healthcare providers' in the US where the most frequently reported source of knowledge about e-cigarettes were patients (62%) or news stories (39%) \[[@b34-medscimonit-25-6322]\]. A study conducted with members of The British Thoracic Oncology Group revealed that 81% of clinicians reported being asked about e-cigarettes by patients \[[@b37-medscimonit-25-6322]\]. Similarly, approximately 70% of primary-care physicians, pulmonologists, and surgeons in the US were asked about e-cigarettes by their patients \[[@b38-medscimonit-25-6322]\]. Despite such a high interest in e-cigarettes among patients, many studies show that healthcare professionals feel uncomfortable discussing e-cigarettes \[[@b34-medscimonit-25-6322],[@b38-medscimonit-25-6322]--[@b40-medscimonit-25-6322]\]. Among lung-cancer specialists in South Korea, 83% reported being uncomfortable when discussing e-cigarettes with their patients \[[@b39-medscimonit-25-6322]\]. In the US, more than half of pediatricians and primary-care physicians reported that they are not confident about their level of knowledge about e-cigarettes and ability to answer questions about e-cigarettes \[[@b34-medscimonit-25-6322],[@b38-medscimonit-25-6322],[@b41-medscimonit-25-6322]\]. Healthcare professionals in the UK were hesitant before advising and potentially prescribing e-cigarettes \[[@b40-medscimonit-25-6322]\]. General practitioners and nurses in the UK suggested that they need more evidence on e-cigarettes to feel comfortable in advising and potentially offering e-cigarettes to their patients \[[@b40-medscimonit-25-6322]\]. In our study, only a quarter of participants declared a high level of knowledge about e-cigarettes, and three-quarters of physicians expressed their willingness to learn more about e-cigarettes. The aforementioned data indicate an urgent need to provide all healthcare providers with unbiased, evidence-based knowledge about e-cigarettes and their impact on health.

There is no scientific consensus about whether e-cigarette use can be used as a harm reduction tool. According to the experts of US National Academies of Sciences, Engineering, and Medicine (NASEM), e-cigarettes may pose less risk for health than combustible tobacco cigarettes and might also increase smoking cessation rates among adult tobacco smokers \[[@b9-medscimonit-25-6322]\]. A different statement is presented by the European Respiratory Society Tobacco Control Committee (ERS TCC) \[[@b18-medscimonit-25-6322]\]. The ERS committee stated that tobacco harm reduction strategies are based upon incorrect assumptions and undocumented claims about safety and effectiveness of alternative nicotine delivery products (including e-cigarettes) for smoking cessation \[[@b18-medscimonit-25-6322]\]. In the opinion of the ERS, e-cigarettes should not be used as a population-based strategy in tobacco control \[[@b18-medscimonit-25-6322]\].

In our study, according to the majority of respondents, e-cigarettes were considered as harmful both for user and bystanders. This is consistent with previously published data on beliefs about e-cigarettes among healthcare professionals from other countries \[[@b33-medscimonit-25-6322],[@b34-medscimonit-25-6322],[@b42-medscimonit-25-6322],[@b43-medscimonit-25-6322]\]. In our study, over 80% of participants agreed that e-cigarette use increases the risk of cancer, cardiovascular, and chronic lung diseases. However, the health risks of e-cigarette use were perceived as lower than those of conventional cigarettes. More in depth consideration of the harmfulness of e-cigarettes among physicians who practice in the hospital may be a result of the fact that they encounter patients with more severe clinical cases compared to physicians working in the ambulatory care.

A group particularly exposed to the harmful effects of nicotine are adolescents whose developing brains are particularly sensitive to the impact of nicotine, including their addictive potential \[[@b44-medscimonit-25-6322],[@b45-medscimonit-25-6322]\]. In our study, physicians almost unanimously agreed that e-cigarettes are addictive and their use by adolescents can lead to conventional cigarette use in the future ("the gateway effect"). Similar results were obtained in studies performed among physicians in the US, UK, and Belgium \[[@b33-medscimonit-25-6322],[@b34-medscimonit-25-6322],[@b40-medscimonit-25-6322]\]. Three-quarters of US physicians believed that e-cigarettes could be a "gateway" to combustible tobacco products use \[[@b34-medscimonit-25-6322]\]. A qualitative interview study revealed that physicians and nurses in the UK are aware of the safety of e-cigarettes and implications of their use on future nicotine dependence \[[@b40-medscimonit-25-6322]\]. The vast majority (83%) of healthcare professionals in Belgium declared that e-cigarettes will cause renormalization of smoking and can lead to uptake of conventional cigarettes \[[@b33-medscimonit-25-6322]\]. Despite the differences in approach to the harm reduction strategy presented in the statement prepared by the NASEM and the ERS, both organizations point to the possibility of a "gateway effect" and risk for transition from e-cigarette to combustible tobacco products among youth who started nicotine use with e-cigarettes \[[@b9-medscimonit-25-6322],[@b18-medscimonit-25-6322]\].

E-cigarettes are promoted as a smoking cessation method \[[@b46-medscimonit-25-6322]\]. Currently available evidence on the effectiveness of e-cigarettes in quitting smoking is debatable and further research is needed \[[@b47-medscimonit-25-6322],[@b48-medscimonit-25-6322]\]. In this study, the largest variation in answers was found in the case of questions about the potential role of e-cigarettes as a tool in smoking cessation, especially among people who do not want to or failed to quit. The issue of recommending e-cigarettes to smokers and encouraging smokers to switch to e-cigarettes raises concerns among physicians globally \[[@b28-medscimonit-25-6322],[@b33-medscimonit-25-6322],[@b34-medscimonit-25-6322],[@b37-medscimonit-25-6322]--[@b42-medscimonit-25-6322]\]. Generally, physicians do not recommend e-cigarettes for smoking cessation due to the lack of evidence on their effectiveness and uncertainty regarding short-term and long-term safety \[[@b43-medscimonit-25-6322]\]. The proportion of physicians who recommend e-cigarettes to the patients vary from 3.7% in the UK \[[@b37-medscimonit-25-6322]\], 12% in South Korea \[[@b39-medscimonit-25-6322]\], 33% in Greece \[[@b49-medscimonit-25-6322]\], and up to 37.9% in the US \[[@b2-medscimonit-25-6322]\]. In our study, 13.3% of physicians declared that they would recommend e-cigarettes to smoking patients, wherein only 1.5% of participants totally agreed with this statement. In the US, resident-physicians are less likely to recommend e-cigarettes to patients than practicing physicians \[[@b43-medscimonit-25-6322]\]. In our study, specialists compared to physicians-in-training more often declared concerns about harmfulness of e-cigarettes, however, the frequency of recommendation of e-cigarettes to the patients was comparable (*P*\>0.05) in both groups. Further studies are needed to assess the effect of e-cigarette use for smoking cessation and to achieve a scientific consensus on the role of e-cigarettes in quitting smoking.

This is one of the largest studies assessing perceptions of e-cigarettes among physicians. Our study has an important implication for public health, especially in view of shaping the policies on tobacco control. Results of our study support the call for further training and support of healthcare professionals regarding e-cigarette use, so that they may provide their patients with evidence-based information regarding e-cigarettes \[[@b32-medscimonit-25-6322]\]. The group that should be particularly aware of e-cigarettes and their potential benefits and risks to health are primary care physicians responsible for providing smoking cessation intervention among smokers. In addition, our study can be a basis for further research, especially among individual groups of specialists, including general practitioners, oncologists, pulmonologists and psychiatrists.

This study has several limitations. First, it was narrowed down to a selected group of physicians attending a course at the School of Public Health, the Centre of Postgraduate Medical Education in Warsaw, Poland. However, participation in the course is compulsory for each of 25 000 physician undergoing specialty training in Poland and the group participating in the study represented different regions and healthcare institutions from all over Poland. Second, questions regarding perceptions of e-cigarettes were based on a 4-point scale. The interpretation of participants' answers on these items may be problematic. Nevertheless, during the preparation of the questionnaire we tried to narrow down and refine the questions in detail. In addition, the results of the pilot study, where the questionnaire was validated, made it possible to develop a final precise research tool. Third, our findings should be interpreted with caution as they reflect general physicians' attitudes and beliefs towards e-cigarettes, rather than the precise risk estimates.

Conclusions
===========

Physicians in Poland perceive e-cigarettes as harmful and addictive, whereas the health risk of e-cigarettes use is perceived as lower than those of conventional cigarettes. Beliefs about the role of e-cigarette as a smoking cessation tool are diverse. Physicians' knowledge about e-cigarettes is mostly based on non-scientific sources. Our study points out the urgent need to develop national smoking cessation guidelines regulating the use of e-cigarettes.

**Source of support:** Departmental sources

![Source of physician knowledge about e-cigarettes.](medscimonit-25-6322-g001){#f1-medscimonit-25-6322}

###### 

Beliefs and attitudes about e-cigarettes among physicians who were aware of e-cigarettes (n=411).

                                                                                                                        Totally disagree % (95% CI)   Rather disagree % (95% CI)   Rather agree % (95% CI)   Totally agree % (95% CI)
  --------------------------------------------------------------------------------------------------------------------- ----------------------------- ---------------------------- ------------------------- --------------------------
  **Health effects of e-cigarette use**                                                                                                                                                                      
  E-cigarettes use is harmful for health of the user                                                                    0.7 (0.3--2.1)                2.7 (1.5--4.8)               38.1 (33.6--42.9)         58.4 (53.6--63.1)
  E-cigarette aerosol is harmful for people in the vicinity of the users                                                1.7 (0.8--3.5)                17.9 (14.5--21.9)            50.3 (45.4--55.1)         30.2 (25.9--34.8)
  E-cigarettes are less harmful than conventional cigarettes                                                            13.7 (10.7--17.4)             27.2 (23.1--31.7)            47.3 (42.5--52.2)         11.8 (9.0--15.3)
  E-cigarettes are carcinogenic                                                                                         0.7 (0.3--2.1)                13.2 (10.3--16.8)            50.6 (45.8--55.4)         35.5 (31.0--40.2)
  The risk of cancer is lower for the e-cigarettes than for the conventional cigarettes                                 8.7 (6.4--11.9)               27.7 (23.6--32.2)            53.6 (48.8--58.4)         10.0 (7.4--13.2)
  E-cigarette use increases the risk of cardiovascular diseases, including myocardial infarction and stroke             1.0 (0.4--2.5)                9.3 (6.9--12.5)              53.4 (48.6--58.2)         36.3 (31.8--41.1)
  The risk of cardiovascular diseases is lower for the e-cigarettes than for the conventional cigarettes                11.2 (8.5--14.6)              32.1 (27.8--36.8)            50.1 (45.3--54.9)         6.6 (4.6--9.4)
  E-cigarette use increases the risk of chronic lung diseases, including COPD                                           1.0 (0.4--2.5)                13.8 (10.8--17.5)            50.5 (45.7--55.3)         34.7 (30.3--39.4)
  The risk of chronic lung diseases is lower for the e-cigarettes than for the conventional cigarettes                  10.5 (7.9--13.8)              32.6 (28.3--37.3)            49.4 (44.6--54.2)         7.5 (5.4--10.5)
  **Addictive potential of e-cigarettes use**                                                                                                                                                                
  E-cigarettes could be a „gateway" to conventional cigarettes use in the future                                        1.9 (1.0--3.8)                10.7 (8.1--14.1)             45.7 (41.0--50.6)         41.6 (36.9--46.4)
  You can become addicted to the e-cigarette                                                                            1.0 (0.4--2.5)                1.9 (1.0--3.8)               30.4 (26.2--35.0)         66.7 (62.0--71.1)
  E-cigarettes are less addictive than conventional cigarettes                                                          32.9 (28.5--37.6)             46.9 (42.1--51.8)            18.2 (14.7--22.2)         2.0 (1.0--3.8)
  E-cigarettes should be recommended as a smoking cessation tool                                                        43.3 (38.6--48.1)             43.3 (38.6--48.1)            11.5 (8.8--15.0)          1.9 (1.0--3.8)
  Smokers who do not want to quit smoking, should be offered and encouraged to use e-cigarettes                         30.8 (26.5--35.4)             35.2 (30.7--40.0)            30.8 (26.5--35.4)         3.2 (1.9--5.4)
  Smokers who failed to quit with conventional smoking cessation should be offered and encouraged to use e-cigarettes   24.3 (20.4--28.6)             32.0 (27.7--36.7)            39.8 (35.2--44.6)         3.9 (2.4--6.2)
  I recommend the e-cigarettes to my patients smoking conventional cigarettes                                           48.5 (43.7--53.4)             38.2 (33.7--43.0)            11.8 (9.0--15.3)          1.5 (0.7--3.2)
  Discussing e-cigarettes with patients may encourage them to use e-cigarettes                                          15.6 (12.4--19.4)             35.6 (31.1--40.4)            43.9 (39.2--48.7)         4.9 (3.2--7.4)
  **Regulation of e-cigarettes**                                                                                                                                                                             
  E-cigarette promotion and advertising should be banned                                                                4.2 (2.6--6.6)                11.5 (8.8--15.0)             29.4 (25.2--34.0)         54.9 (50.1--59.7)
  E-cigarettes should be prohibited to minors (under 18 years)                                                          2.2 (1.2--4.1)                0.7 (0.3--2.1)               10.5 (7.9--13.8)          86.6 (82.9--89.6)
  E-cigarettes use in public places should be banned                                                                    3.6 (2.2--5.9)                7.5 (5.4--10.5)              22.8 (19.0--27.1)         66.0 (61.3--70.4)
  E-cigarettes use should be banned indoors                                                                             3.4 (2.0--5.6)                4.9 (3.2--7.4)               19.4 (15.9--23.5)         72.3 (67.8--76.4)
  E-cigarettes should be regulated in the same way as tobacco products                                                  4.1 (2.6--6.5)                7.3 (5.2--10.2)              18.7 (15.2--22.7)         69.9 (65.3--74.1)

###### 

Participant characteristics (n=412).

                                                              n (%)
  ----------------------------------------------------------- -------------------
  **Age (years)**, mean±SD, (min--max)                        31.9±5.7 (26--64)
  **Sex**                                                     
  Male                                                        147 (35.7)
  Female                                                      265 (64.3)
  **Medical education level**                                 
  In-training (during specialization)                         353 (85.7)
  Specialist                                                  59 (14.3)
  **Specialty (n=390)**                                       
  Surgical                                                    106 (27.2)
  Non-Surgical                                                284 (72.8)
  **Years of professional experience,** mean±SD, (min--max)   5.8±5.2 (1--35)
  **Place of primary employment (practice type)**             
   Hospital                                                   367 (89.1)
  Ambulatory                                                  45 (10.9)
  **Practice location**                                       
  Rural                                                       9 (2.2)
   City up to 200 000 residents                               120 (29.1)
   City from 200 000 to 500,000 residents                     66 (16.0)
   City above 500 000 residents                               217 (52.7)

SD -- standard deviation.

###### 

Physicians' awareness and knowledge about e-cigarettes (n=412).

                                                     \% (95% CI)
  -------------------------------------------------- --------------------
  **Awareness of e-cigarettes**                      
  Yes                                                99.8 (98.6--100.0)
  No                                                 0.2 (0.0--1.4)
  **Self-reported knowledge about e-cigarettes**     
  Nothing at all                                     1.9 (1.0--3.8)
  A little                                           24.3 (20.4--28.6)
  A moderate                                         50.8 (45.9--55.5)
  Somewhat strong                                    21.1 (17.5--25.3)
  Strong                                             1.9 (1.0--3.8)
  **Willingness to learn more about e-cigarettes**   
  Strongly disagree                                  3.2 (1.9--5.3)
  Somewhat disagree                                  18.7 (15.2--22.7)
  Somewhat agree                                     49.5 (44.7--54.3)
  Strongly agree                                     28.6 (24.5--33.2)

CI -- confidence interval.
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